Research programme: ubiquitin-proteasome inhibitors - Millennium/Roche

Drug Profile

Research programme: ubiquitin-proteasome inhibitors - Millennium/Roche

Alternative Names: Ubiquitin-proteasome inhibitors research programme - Millennium/Roche

Latest Information Update: 31 May 2006

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals; Roche
  • Class
  • Mechanism of Action Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Cachexia

Most Recent Events

  • 31 Dec 2005 No development reported - Preclinical for Cachexia in USA (unspecified route)
  • 15 Dec 1997 Preclinical development for Cachexia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top